hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06362408, orgStudyIdInfo id: PLAGH-DEX-PSM/IPTW-001, briefTitle: Effect of Dexmedetomidine on Postoperative Mental Disorders and Long-term Survival in Elderly Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-06-01, primaryCompletionDateStruct date: 2023-05-25, completionDateStruct date: 2023-06-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Chinese PLA General Hospital, class: OTHER, collaborators name: Beijing Tiantan Hospital, collaborators name: First Affiliated Hospital of Guangxi Medical University, collaborators name: The Affiliated Hospital Of Guizhou Medical University, collaborators name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, collaborators name: Wuhan Union Hospital, China, collaborators name: Fudan University, descriptionModule briefSummary: China's aging population is causing an increase in the number of senior persons undergoing surgery. More and more clinicians are paying attention to the postoperative survival and mental health of elderly surgical patients.Dexmedetomidine (DEX) is an alpha-2 adrenergic agonist that works by inhibiting norepinephrine releasing renaline, which reduces inflammation and thus plays a protective role in the central nervous system. DEX has the potential to prevent and treat postoperative anxiety and depression in elderly patients undergoing non-cardiac surgery.Further exploration of evidence for evidence-based medicine is needed. Based on the above research background, this hypothesis is proposed: in elderly patients undergoing noncardiac surgery, intraoperative DEX is associated with a reduction in short-term postoperative mental disorders and a reduction in long-term postoperative mortality., conditionsModule conditions: Cohort Studies, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 6000, type: ACTUAL, armsInterventionsModule interventions name: Dexmedetomidine, outcomesModule primaryOutcomes measure: Postoperative mortality rate, secondaryOutcomes measure: The incidence of postoperative delirium, secondaryOutcomes measure: The incidence of postoperative anxiety, secondaryOutcomes measure: The incidence of postoperative depression, secondaryOutcomes measure: Postoperative sleep disorders, secondaryOutcomes measure: Surgical related complications, secondaryOutcomes measure: Postoperative quality of life evaluation, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 110 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chinese PLA General Hospital, city: Beijing, state: Beijing, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06362356, orgStudyIdInfo id: 24-106, briefTitle: Microbial Metabolites and Outcomes of Pregnancy Study, acronym: MMOPS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-05, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: The Cleveland Clinic, class: OTHER, descriptionModule briefSummary: Emerging data connect diet, the gut microbiota and its metabolites in cardiometabolic disease. Hypertensive disorders of pregnancy (HDP) are common and are a leading cause of maternal and neonatal morbidity. HDP likely share similar pathophysiology as cardiometabolic disease in non-pregnant people with a yet unrevealed role of diet and the gut microbiota, including systemic inflammation and endothelial dysfunction.Despite high biological plausibility that nutrition, the gut microbiota and its metabolites may play a role in health and disease in pregnancy, there is a paucity of data regarding these associations, thus limiting advancement of the field. Similar to the proposed pathogenesis for diet, gut microbiota and the microbial metabolite trimethylamine-N-oxide (TMAO) in cardiovascular disease, we hypothesize that the interplay between maternal diet, the gut microbiota and its associated microbial metabolites play a mechanistic role in HDP. We propose to test this hypothesis in a racially-diverse US cohort to determine association with adverse pregnancy outcomes, specifically future development of HDP. We propose to prospectively collect plasma and urine TMAO throughout pregnancy from a cohort of 200 pregnant participants.Through 1) characterizing plasma and urine TMAO levels across each trimester of pregnancy, and 2) assessment of this microbial metabolite as a predictor of development of HDP, we have the potential to identify a biomarker that would allow us to identify people at risk of HDP early in pregnancy and provide new opportunities for therapeutic interventions to improve maternal and neonatal outcomes., conditionsModule conditions: Hypertensive Disorder of Pregnancy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: TMAO level, primaryOutcomes measure: TMAO level, primaryOutcomes measure: TMAO level, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Cleveland Clinic, status: RECRUITING, city: Cleveland, state: Ohio, zip: 44195, country: United States, contacts name: Cara Dolin, M.D., role: CONTACT, phone: 440-312-2229, email: dolinc@ccf.org, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False
protocolSection identificationModule nctId: NCT06362343, orgStudyIdInfo id: PUMCH-Rivaroxaban-Monitoring, briefTitle: The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2026-10-30, completionDateStruct date: 2027-01-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, collaborators name: Ruijin Hospital, collaborators name: Xiangya Hospital of Central South University, collaborators name: China-Japan Friendship Hospital, descriptionModule briefSummary: 1. Integrate pharmacokinetic-pharmacodynamic (PK-PD) modeling and pharmacogenomics techniques to develop a population PK-PD model, aiming to explore monitoring and dose guidance schemes for Direct Oral Anticoagulants (DOACs).2. Investigate the factors influencing PK-PD of DOACs in the pulmonary embolism population, clarifying the correlation between genotype characteristics and clinical outcomes.3. Explore the correlation between drug concentrations, coagulation indices, and clinical outcomes of DOACs, defining the indications for DOACs testing and the overall monitoring process., conditionsModule conditions: Pulmonary Embolism, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Rivaroxaban, outcomesModule primaryOutcomes measure: Bleeding events, primaryOutcomes measure: Recurrent thromboembolic events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 120 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking Union Medical College Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100730, country: China, contacts name: Juhong Shi, M.D, role: CONTACT, phone: +8613701178492, email: shijh@pumch.cn, contacts name: Min Peng, M.D, role: CONTACT, phone: +8613581888792, email: pengmin@pumch.cn, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06362330, orgStudyIdInfo id: 2022-SR-471, briefTitle: Multi-parametric MRI in Patients of Bladder Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-07-01, primaryCompletionDateStruct date: 2024-05-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: Accurate preoperative detection of muscle-invasive bladder cancer remains a clinical challenge. The investigators aimed to develop and validate a knowledge-guided causal diagnostic network for the detection of muscle-invasive bladder cancer with multiparametric magnetic resonance imaging(MRI)., conditionsModule conditions: Muscle-invasive Bladder Cancer, conditions: Artificial Intelligence, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: magnetic resonance imaging, outcomesModule primaryOutcomes measure: Muscle-invasive bladder cancer, primaryOutcomes measure: Non-muscle-invasive bladder cancer, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Yu-Dong Zhang, status: RECRUITING, city: Nanjing, zip: 210029, country: China, contacts name: Yu-Dong Zhang, MD;PHD, role: CONTACT, phone: 15805151704, email: njmu_zyd@163.com, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06362317, orgStudyIdInfo id: K5247, briefTitle: Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-06, primaryCompletionDateStruct date: 2025-03-06, completionDateStruct date: 2026-03-06, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, descriptionModule briefSummary: Explore the impact of the first-line application of Toripalimab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers, conditionsModule conditions: Biliary Tract Neoplasms Immunotherapy, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Toripalimab, interventions name: Lenvatinib, interventions name: Gemox Chemotherapy（Gemox or GC）, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Duration of response, secondaryOutcomes measure: Clinical benefit rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), status: RECRUITING, city: Beijing, state: Beijing, zip: 100005, country: China, contacts name: Haitao Zhao, Professor, role: CONTACT, phone: +861069156042, email: zhaoht@pumch.cn, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06362304, orgStudyIdInfo id: 2024-DG-01, briefTitle: 99mTc-CNDG SPECT/CT in Brain Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are:1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG?2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type?Participants will:Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard., conditionsModule conditions: Intracranial Tumor, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: 99mTc-CNDG SPECT/CT, outcomesModule primaryOutcomes measure: SUVmax, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362291, orgStudyIdInfo id: 2023IR27, briefTitle: Comparison of MRI AI-cTB Versus Routine cTB in Prostate Cancer Diagnosis: a Prospective Randomized Controlled Trial, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-08-01, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Peking University First Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare the cancer detection rates of MRI artificial intelligence-guided cTB (AI-cTB) and routine cTB, and explore the added value of using AI for the guidance of cTB. The main questions it aims to answer are:Does AI-cTB promote the accurate diagnosis and treatment of prostate cancer? What's the value of prostate MRI artificial intelligence assistant diagnosis system in developing the best scheme of prostate biopsy? What's the value of prostate MRI artificial intelligence assistant diagnosis system in predicting the pathological results of prostate targeted biopsy?Researchers will compare the cancer detection rates of AI-cTB and routine cTB to explore the added value of using AI for the guidance of cTB.Participants will:Receive AI-cTB or routine cTB., conditionsModule conditions: Prostate Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 340, type: ESTIMATED, armsInterventionsModule interventions name: MRI-AI guided cognitive prostate targeted biopsy, interventions name: Routine cognitive prostate targeted biopsy, outcomesModule primaryOutcomes measure: The clinically significant prostate cancer (csPCa) detection rate for targeted biopsy (TB) and TB combined with systematic biopsy (SB), secondaryOutcomes measure: The PCa detection rate, secondaryOutcomes measure: The Gleason score (GS) of the biopsy sample, secondaryOutcomes measure: The GS of radical prostatectomy (RP) specimens, eligibilityModule sex: MALE, minimumAge: 45 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University First Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100034, country: China, contacts name: Baowei Zhang, role: CONTACT, phone: +86 83572466, email: bdyyll@126.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06362278, orgStudyIdInfo id: 026, briefTitle: A Multi-omics Study of "Healthy" Premature CAD Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: The goal of this multi-center observational clinical trial is to investigate the genetic risk factors of patients with premature CAD and none traditional CAD risk factors through a multi-omics approach.The main questions it aims to answer are:* Genetic risk factors \& metabolic fingerprints of patients with premature CAD and none traditional CAD risk factors remain unknown.* How to optimize current primary prevention strategy for this rare CAD subgroup？, conditionsModule conditions: Coronary Artery Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 160, type: ESTIMATED, armsInterventionsModule interventions name: multi-omics studies, outcomesModule primaryOutcomes measure: common & rare variants associated with "healthy" pre-mature CAD phenotype, primaryOutcomes measure: Unique metabolomic fingerprints associated with "healthy" pre-mature CAD phenotype, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: First Affiliated Hospital of Nanjing Medical University, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210000, country: China, contacts name: Chunjian Li, Phd、MD, role: CONTACT, phone: +86 13701465229, email: lijay@njmu.edu.cn, geoPoint lat: 32.06167, lon: 118.77778, locations facility: Qilu Hospital of Shangdong University, status: ACTIVE_NOT_RECRUITING, city: Jinan, state: Shandong, zip: 250012, country: China, geoPoint lat: 36.66833, lon: 116.99722, locations facility: The Second Affiliated Hospital of Zhejiang University Medical College, status: ACTIVE_NOT_RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310009, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06362239, orgStudyIdInfo id: STUDY00003853, briefTitle: Prospective Home-Based Palliative Care and Hospice Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-10, completionDateStruct date: 2027-10, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Steven Smith, class: OTHER, collaborators name: Akron Children's Hospital, collaborators name: Medical University of South Carolina, collaborators name: Nemours Children's Hospital, collaborators name: Baylor College of Medicine, descriptionModule briefSummary: The purpose of this study is to test the hypothesis that the addition of home-based hospice and palliative care (HBHPC) will provide a reduction in health care utilization, improve quality of life, and facilitate goal-concordant care that is superior to inpatient and clinic pediatric palliative care (PPC) alone., conditionsModule conditions: Pediatric Palliative Care, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: Study Surveys, outcomesModule primaryOutcomes measure: Hospital Utilization Differences, secondaryOutcomes measure: Demographic Differences, secondaryOutcomes measure: Location of death differences, eligibilityModule sex: ALL, maximumAge: 19 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362226, orgStudyIdInfo id: HM20029491, briefTitle: OPTIMIZING OCULAR OUTCOMES: A DUAL-ARMED STUDY FOR PERIORBITAL BURN MANAGEMENT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-08, completionDateStruct date: 2026-10, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Virginia Commonwealth University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate the effectiveness in using subcutaneous 5-FU/Kenalog \& antibiotic ointment with vitamin E as different therapeutic adjuncts in the prevention of pathologic remodeling after periorbital burns., conditionsModule conditions: Periorbital Burns, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Steroid/Antibiotic, interventions name: 5-FU/Kenalog, outcomesModule primaryOutcomes measure: Comparison of wound healing time, primaryOutcomes measure: Comparison of infection rate, primaryOutcomes measure: Comparison of complication rates, secondaryOutcomes measure: Comparison of pain level, secondaryOutcomes measure: Comparison of quality of life, secondaryOutcomes measure: Comparison of cosmetic outcome through the Vancouver scar scale (VSS), secondaryOutcomes measure: Comparison of cosmetic outcome through the Patient Observer Scar Assessment Scale (POSAS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362213, orgStudyIdInfo id: NL76924.029.22, briefTitle: Gaining Insight Into Dual Sensory Loss, acronym: DSL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Amsterdam UMC, location VUmc, class: OTHER, collaborators name: Royal Dutch Visio, descriptionModule briefSummary: The goal of this observational study is to explore difficulties in information access, mobility, communication and fatigue in people with combined vision and hearing impairments. The main question it aims to answer is:• What influence do varying severities of vision and hearing loss have on information access, mobility, communication and fatigue.Participants will fill out questionnaires and the researchers will measure their vision and hearing functions., conditionsModule conditions: Dual Sensory Impairment of Vision and Hearing, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: information access, primaryOutcomes measure: mobility, primaryOutcomes measure: communication, primaryOutcomes measure: fatigue, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Amsterdam UMC, location VUmc, city: Amsterdam, state: Noord Holland, zip: 1081 HV, country: Netherlands, geoPoint lat: 52.37403, lon: 4.88969, hasResults: False